IP Library › Granted Patent US 10,472,361
Granted Patent B2
US 10,472,361 · App. 16/103,210 · Granted Nov 12, 2019

Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor

Inventors: Yam B. Poudel (Fremont, CA); Sanjeev Gangwar (Foster City, CA); Prasanna Sivaprakasam (Lawrenceville, NJ); Shoshana L. Posy (Highland Park, NJ)
Assignee: Bristol-Myers Squibb Company
C07D473/18A61P37/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,472,361
App. No.
16/103,210
Granted
Nov 12, 2019
Kind
B2
Abstract

Compounds having a structure according to formula (I) where R 1 , R 2 , and R 3 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.

Claims (15)

1. A compound having a structure according to formula (I)

wherein

R 1 is (C 1 -C 5 alkyl)O, (C 1 -C 2 alkyl)O(CH 2 ) 2-3 O, (C 1 -C 5 alkyl)C(═O)O, (C 1 -C 5 alkyl)NH, (C 1 -C 2 alkyl)O(CH 2 ) 2-3 NH, or (C 1 -C 5 alkyl)C(═O)NH;

R 2 is, independently for each occurrence thereof, H, C 1 -C 3 alkyl, halo, O(C 1 -C 3 alkyl), CN, or NO 2 ;

R 3 is H, Me, or (CH 2 ) x R 4 , where the subscript x is 2, 3, or 4; and

R 4 is H, halo, OH, CN, NH 2 , NH(C 1 -C 5 alkyl), N(C 1 -C 5 alkyl) 2 , NH(C 3 -C 6 cycloalkyl), NH(C 4 -C 8 bicycloalkyl), NH(C 6 -C 10 spirocycloalkyl), N(C 3 -C 6 cycloalkyl) 2 , NH(CH 2 ) 1-3 (aryl), N((CH 2 ) 1-3 (aryl)) 2 , a cyclic amine moiety having the structure

 a 6-membered aromatic or heteroaromatic moiety or a 5-membered heteroaromatic moiety;

wherein

an alkyl, cycloalkyl, bicycloalkyl, spriocycloalkyl, cyclic amine, 6-membered aromatic or heteroaromatic, or 5-membered heteroaromatic moiety is optionally substituted with one or more substituents selected from OH, halo, CN, (C 1 -C 3 alkyl), O(C 1 -C 3 alkyl), C(═O)(Me), SO 2 (C 1 -C 3 alkyl), C(═O)(Et), NH 2 , NH(Me), N(Me) 2 , NH(Et), N(Et) 2 , and N(C 1 -C 3 alkyl) 2 ; and

a cycloalkyl, bicycloalkyl, sprioalkyl, or cyclic amine moiety may have a CH 2 group replaced by O, S, NH, N(C 1 -C 3 alkyl), or N(t-butyoxycarbonyl).

2. A compound according to claim 1 , wherein R 1 is n-BuO or MeOCH 2 CH 2 O and R 4 is OH, Cl,

3. A compound according to claim 1 , having a structure represented by formula (Ia)

4. A compound according to claim 3 , wherein R 1 is n-BuO or MeOCH 2 CH 2 O and R 4 is OH, Cl,

5. A compound according to claim 4 , wherein R 1 is n-BuO.

6. A compound according to claim 1 , selected from the group consisting of

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2019
From: POUDEL, YAM B.; GANGWAR, SANJEEV; SIVAPRAKASAM, PRASANNA; POSY, SHOSHANA L.
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 049428/0947 →
Continuity (2)
Provisional Application 62546095 · Aug 16, 2017
Related Publication 20190055243A1 · Feb 21, 2019
Cited By (1)
US 12,485,123